Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies

BACKGROUND: No validated biomarkers currently exist for predicting the efficacy outcomes in patients with neuroendocrine tumors (NETs) treated with antiangiogenic therapy. We aimed to evaluate the association between treatment-related adverse events (TRAEs) and efficacy outcomes of surufatinib in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, J., Cheng, Y., Bai, C., Xu, J., Shen, L., Zhou, Z., Li, Z., Chi, Y., Yu, X., Li, E., Xu, N., Liu, T., Lou, W., Bai, Y., Yuan, X., Wang, X., Yuan, Y., Chen, J., Guan, S., Fan, S., Su, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058866/
https://www.ncbi.nlm.nih.gov/pubmed/35344750
http://dx.doi.org/10.1016/j.esmoop.2022.100453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058866/
https://www.ncbi.nlm.nih.gov/pubmed/35344750
http://dx.doi.org/10.1016/j.esmoop.2022.100453

Ejemplares similares